<div id="readability-page-1"><p>LaSalle St. Investment Advisors LLC grew its stake in  Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 16.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,356 shares of the company's stock after acquiring an additional 1,776 shares during the period. LaSalle St. Investment Advisors LLC's holdings in Johnson &amp; Johnson were worth $2,049,000 as of its most recent filing with the Securities and Exchange Commission.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>Worried About a Fading Rally? Consider These 3 Dividend Stocks</li></ul><p>Other large investors also recently modified their holdings of the company. Elios Financial Group Inc. boosted its stake in  Johnson &amp; Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after purchasing an additional 66 shares during the period.  Atlantic Family Wealth LLC boosted its position in shares of  Johnson &amp; Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after acquiring an additional 67 shares in the last quarter.  MBA Advisors LLC increased its stake in  Johnson &amp; Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after acquiring an additional 68 shares during the last quarter.  Sovereign Financial Group Inc. lifted its stake in  Johnson &amp; Johnson by 1.8% during the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after purchasing an additional 69 shares during the last quarter.  Finally, Nabity Jensen Investment Management Inc increased its stake in shares of  Johnson &amp; Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after purchasing an additional 69 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Wall Street Analyst Weigh In</h2><p>Several brokerages recently commented on JNJ. Wall Street Zen lowered Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Friday, July 18th. UBS Group lifted their price objective on Johnson &amp; Johnson from $180.00 to $190.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, July 17th. Piper Sandler  reiterated an &#34;overweight&#34; rating on shares of Johnson &amp; Johnson in a research report on Thursday, July 17th. Bank of America lifted their price objective on Johnson &amp; Johnson from $161.00 to $175.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, July 17th. Finally, Benchmark upgraded Johnson &amp; Johnson to a &#34;strong-buy&#34; rating in a report on Thursday, April 24th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $174.50.</p><ul><li>3 Big Dividend Plays With Strong Earnings to Back Them</li></ul><p><b>Get Our Latest Stock Report on Johnson &amp; Johnson</b></p><h2>Johnson &amp; Johnson Stock Performance</h2><p>Shares of JNJ opened at $171.41 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson &amp; Johnson has a one year low of $140.68 and a one year high of $172.18. The company's fifty day moving average price is $158.89 and its 200 day moving average price is $157.27. The company has a market capitalization of $412.81 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 2.17 and a beta of 0.41. </p><ul><li>4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson &amp; Johnson had a return on equity of 32.49% and a net margin of 25.00%. Johnson &amp; Johnson's revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.82 earnings per share.  As a group, analysts expect that  Johnson &amp; Johnson will post 10.58 earnings per share for the current year. </p><h2>Johnson &amp; Johnson Dividend Announcement</h2><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson &amp; Johnson's dividend payout ratio (DPR) is currently 55.61%. </p><h2>Johnson &amp; Johnson Profile</h2> (Free Report)<p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>How to Calculate Stock Profit </li><li>3 AI Infrastructure Stocks Powering the Next Tech Revolution</li><li>How to Use the MarketBeat Stock Screener </li><li>Why Monolithic Power's Earnings and Guidance Ignited a Rally</li><li>What is the Dogs of the Dow Strategy? Overview and Examples</li><li>AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>LaSalle St. Investment Advisors LLC increased its stake in Johnson & Johnson (NYSE: JNJ) by 16.8% in Q1, acquiring an additional 1,776 shares, bringing its total to 12,356 shares valued at $2,049,000. Other investors also adjusted their holdings. Analysts have mixed ratings on JNJ, with a consensus rating of "Moderate Buy" and an average target price of $174.50. JNJ's stock opened at $171.41, with a market cap of $412.81 billion and a PE ratio of 18.33. The company reported $2.77 EPS for the last quarter, exceeding estimates.</p>

LaSalle St. Investment Advisors LLC Acquires 1,776 Shares of Johnson & Johnson (NYSE:JNJ)